A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)
A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)
Enlarged glands in the chest (mediastinal lymphadenopathy) is a common problem and may have a
 variety of different causes. In the past an operation (mediastinoscopy) was required to
 diagnose the glands. Endobronchial ultrasound (EBUS) is a new procedure that may be able to
 diagnose these glands without the need for mediastinoscopy. The REMEDY trial aims to examine
 whether EBUS can reduce the number of mediastinoscopies and healthcare costs in patients with
 enlarged glands in the chest.
Although the literature is replete with data on the utility of Endobronchial Ultrasound for
 lung cancer, there are very few data available on its role in the diagnosis of isolated
 mediastinal lymphadenopathy due to other causes such as sarcoid, tuberculosis or lymphoma.
 The REMEDY trial aims to evaluate the accuracy of EBUS in this setting and assess any
 reduction in the number of mediastinoscopies and healthcare costs.
Inclusion Criteria:

 -  Consecutive patients with undiagnosed mediastinal lymphadenopathy (>1cm in short axis)
 on CT or PET-CT scan for whom pathological evaluation is clinically indicated.

 Exclusion Criteria:

 -  Patients without informed consent, those with anterior mediastinal lesions or with
 contra-indications to EBUS or mediastinoscopy will be excluded.